VanEck Biotech ETF (NASDAQ:BBH) Short Interest Update

VanEck Biotech ETF (NASDAQ:BBHGet Free Report) was the target of a significant decline in short interest during the month of February. As of February 15th, there was short interest totalling 700 shares, a decline of 22.2% from the January 31st total of 900 shares. Based on an average daily trading volume, of 12,700 shares, the short-interest ratio is currently 0.1 days.

VanEck Biotech ETF Stock Performance

Shares of NASDAQ:BBH traded up $3.06 during trading on Friday, reaching $165.80. The stock had a trading volume of 10,023 shares, compared to its average volume of 6,011. The business has a fifty day moving average price of $165.71 and a 200-day moving average price of $159.18. VanEck Biotech ETF has a fifty-two week low of $142.51 and a fifty-two week high of $171.04.

VanEck Biotech ETF Announces Dividend

The company also recently disclosed an annual dividend, which was paid on Friday, December 22nd. Stockholders of record on Tuesday, December 19th were given a $0.7127 dividend. The ex-dividend date of this dividend was Monday, December 18th.

Hedge Funds Weigh In On VanEck Biotech ETF

Institutional investors have recently modified their holdings of the company. Bank of Montreal Can acquired a new position in VanEck Biotech ETF during the second quarter worth approximately $43,000. Kestra Advisory Services LLC increased its position in VanEck Biotech ETF by 16.1% during the third quarter. Kestra Advisory Services LLC now owns 3,061 shares of the company’s stock worth $477,000 after purchasing an additional 424 shares during the last quarter. Wealthfront Advisers LLC increased its position in VanEck Biotech ETF by 32.8% during the third quarter. Wealthfront Advisers LLC now owns 5,229 shares of the company’s stock worth $814,000 after purchasing an additional 1,292 shares during the last quarter. Envestnet Asset Management Inc. increased its position in VanEck Biotech ETF by 5.8% during the second quarter. Envestnet Asset Management Inc. now owns 21,340 shares of the company’s stock worth $3,330,000 after purchasing an additional 1,166 shares during the last quarter. Finally, Private Advisor Group LLC increased its position in VanEck Biotech ETF by 4.7% during the third quarter. Private Advisor Group LLC now owns 1,675 shares of the company’s stock worth $261,000 after purchasing an additional 75 shares during the last quarter. Institutional investors and hedge funds own 36.23% of the company’s stock.

About VanEck Biotech ETF

(Get Free Report)

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.

Read More

Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.